APO Research
Talk to an analyst

APO RESEARCH · REPORT

Myelodysplastic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Myelodysplastic Syndrome Drug Industry Research Report 2026

29 December 2025124 pages

Choose your research edition.

Industry ResearchMyelodysplastic Syndrome Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Myelodysplastic Syndrome Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Myelodysplastic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myelodysplastic Syndrome Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Myelodysplastic Syndrome Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Myelodysplastic Syndrome Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Myelodysplastic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Myelodysplastic Syndrome Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Myelodysplastic Syndrome Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Myelodysplastic Syndrome Drug include BluePoint Laboratories, Celgene Corporation, Lupin Ltd Corporation, Otsuka America Pharmaceutical, Reddy's Laboratories, Shilpa Medicare Limited, Sun Pharmaceutical Industries, Amgen and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Myelodysplastic Syndrome Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Myelodysplastic Syndrome Drug Market by Company

BluePoint Laboratories

Celgene Corporation

Lupin Ltd Corporation

Otsuka America Pharmaceutical

Reddy's Laboratories

Shilpa Medicare Limited

Sun Pharmaceutical Industries

Amgen

Johnson & Johnson

Sandoz

Takeda

Myelodysplastic Syndrome Drug Segment by Type

Immunomodulatory Drugs

Hypomethylating Drugs

Myelodysplastic Syndrome Drug Segment by Application

Hospital

Ambulatory Nursing Center

Others

Myelodysplastic Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myelodysplastic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myelodysplastic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myelodysplastic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Myelodysplastic Syndrome Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Myelodysplastic Syndrome Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Myelodysplastic Syndrome Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Myelodysplastic Syndrome Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Myelodysplastic Syndrome Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Myelodysplastic Syndrome Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Myelodysplastic Syndrome Drug Revenue of Manufacturers (2021-2026) Table 9. Global Myelodysplastic Syndrome Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Myelodysplastic Syndrome Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Myelodysplastic Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Myelodysplastic Syndrome Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Myelodysplastic Syndrome Drug, Product Type & Application Table 14. Global Myelodysplastic Syndrome Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Myelodysplastic Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. BluePoint Laboratories Company Information Table 19. BluePoint Laboratories Business Overview Table 20. BluePoint Laboratories Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. BluePoint Laboratories Myelodysplastic Syndrome Drug Product Portfolio Table 22. BluePoint Laboratories Recent Developments Table 23. Celgene Corporation Company Information Table 24. Celgene Corporation Business Overview Table 25. Celgene Corporation Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Celgene Corporation Myelodysplastic Syndrome Drug Product Portfolio Table 27. Celgene Corporation Recent Developments Table 28. Lupin Ltd Corporation Company Information Table 29. Lupin Ltd Corporation Business Overview Table 30. Lupin Ltd Corporation Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Lupin Ltd Corporation Myelodysplastic Syndrome Drug Product Portfolio Table 32. Lupin Ltd Corporation Recent Developments Table 33. Otsuka America Pharmaceutical Company Information Table 34. Otsuka America Pharmaceutical Business Overview Table 35. Otsuka America Pharmaceutical Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Otsuka America Pharmaceutical Myelodysplastic Syndrome Drug Product Portfolio Table 37. Otsuka America Pharmaceutical Recent Developments Table 38. Reddy's Laboratories Company Information Table 39. Reddy's Laboratories Business Overview Table 40. Reddy's Laboratories Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Reddy's Laboratories Myelodysplastic Syndrome Drug Product Portfolio Table 42. Reddy's Laboratories Recent Developments Table 43. Shilpa Medicare Limited Company Information Table 44. Shilpa Medicare Limited Business Overview Table 45. Shilpa Medicare Limited Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Shilpa Medicare Limited Myelodysplastic Syndrome Drug Product Portfolio Table 47. Shilpa Medicare Limited Recent Developments Table 48. Sun Pharmaceutical Industries Company Information Table 49. Sun Pharmaceutical Industries Business Overview Table 50. Sun Pharmaceutical Industries Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sun Pharmaceutical Industries Myelodysplastic Syndrome Drug Product Portfolio Table 52. Sun Pharmaceutical Industries Recent Developments Table 53. Amgen Company Information Table 54. Amgen Business Overview Table 55. Amgen Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Amgen Myelodysplastic Syndrome Drug Product Portfolio Table 57. Amgen Recent Developments Table 58. Johnson & Johnson Company Information Table 59. Johnson & Johnson Business Overview Table 60. Johnson & Johnson Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Johnson & Johnson Myelodysplastic Syndrome Drug Product Portfolio Table 62. Johnson & Johnson Recent Developments Table 63. Sandoz Company Information Table 64. Sandoz Business Overview Table 65. Sandoz Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sandoz Myelodysplastic Syndrome Drug Product Portfolio Table 67. Sandoz Recent Developments Table 68. Takeda Company Information Table 69. Takeda Business Overview Table 70. Takeda Myelodysplastic Syndrome Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Takeda Myelodysplastic Syndrome Drug Product Portfolio Table 72. Takeda Recent Developments Table 73. Global Myelodysplastic Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 74. Global Myelodysplastic Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 75. Global Myelodysplastic Syndrome Drug Sales Market Share by Region (2021-2026) Table 76. Global Myelodysplastic Syndrome Drug Sales by Region (2027-2032) & (K Units) Table 77. Global Myelodysplastic Syndrome Drug Sales Market Share by Region (2027-2032) Table 78. Global Myelodysplastic Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 79. Global Myelodysplastic Syndrome Drug Revenue Market Share by Region (2021-2026) Table 80. Global Myelodysplastic Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 81. Global Myelodysplastic Syndrome Drug Revenue Market Share by Region (2027-2032) Table 82. North America Myelodysplastic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. North America Myelodysplastic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 84. North America Myelodysplastic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 85. North America Myelodysplastic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Myelodysplastic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Europe Myelodysplastic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Europe Myelodysplastic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 89. Europe Myelodysplastic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 90. Europe Myelodysplastic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Myelodysplastic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Asia Pacific Myelodysplastic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Asia Pacific Myelodysplastic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 94. Asia Pacific Myelodysplastic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 95. Asia Pacific Myelodysplastic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Asia Pacific Myelodysplastic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. South America Myelodysplastic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. South America Myelodysplastic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 99. South America Myelodysplastic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 100. South America Myelodysplastic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. South America Myelodysplastic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Middle East and Africa Myelodysplastic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Middle East and Africa Myelodysplastic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 104. Middle East and Africa Myelodysplastic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 105. Middle East and Africa Myelodysplastic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. Middle East and Africa Myelodysplastic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Global Myelodysplastic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 108. Global Myelodysplastic Syndrome Drug Sales by Type (2027-2032) & (K Units) Table 109. Global Myelodysplastic Syndrome Drug Sales Market Share by Type (2021-2026) Table 110. Global Myelodysplastic Syndrome Drug Sales Market Share by Type (2027-2032) Table 111. Global Myelodysplastic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. Global Myelodysplastic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. Global Myelodysplastic Syndrome Drug Revenue Market Share by Type (2021-2026) Table 114. Global Myelodysplastic Syndrome Drug Revenue Market Share by Type (2027-2032) Table 115. Global Myelodysplastic Syndrome Drug Price by Type (2021-2026) & (US$/Unit) Table 116. Global Myelodysplastic Syndrome Drug Price by Type (2027-2032) & (US$/Unit) Table 117. Global Myelodysplastic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 118. Global Myelodysplastic Syndrome Drug Sales by Application (2027-2032) & (K Units) Table 119. Global Myelodysplastic Syndrome Drug Sales Market Share by Application (2021-2026) Table 120. Global Myelodysplastic Syndrome Drug Sales Market Share by Application (2027-2032) Table 121. Global Myelodysplastic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 122. Global Myelodysplastic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 123. Global Myelodysplastic Syndrome Drug Revenue Market Share by Application (2021-2026) Table 124. Global Myelodysplastic Syndrome Drug Revenue Market Share by Application (2027-2032) Table 125. Global Myelodysplastic Syndrome Drug Price by Application (2021-2026) & (US$/Unit) Table 126. Global Myelodysplastic Syndrome Drug Price by Application (2027-2032) & (US$/Unit) Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Myelodysplastic Syndrome Drug Distributors List Table 130. Myelodysplastic Syndrome Drug Customers List Table 131. Myelodysplastic Syndrome Drug Industry Trends Table 132. Myelodysplastic Syndrome Drug Industry Drivers Table 133. Myelodysplastic Syndrome Drug Industry Restraints Table 134. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Myelodysplastic Syndrome Drug Product Image Figure 5. Global Myelodysplastic Syndrome Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Myelodysplastic Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Myelodysplastic Syndrome Drug Sales (2021-2032) & (K Units) Figure 8. Global Myelodysplastic Syndrome Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Immunomodulatory Drugs Product Image Figure 10. Hypomethylating Drugs Product Image Figure 11. Hospital Product Image Figure 12. Ambulatory Nursing Center Product Image Figure 13. Others Product Image Figure 14. Global Myelodysplastic Syndrome Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Myelodysplastic Syndrome Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Myelodysplastic Syndrome Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Myelodysplastic Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Myelodysplastic Syndrome Drug Sales by Region in 2025 Figure 20. Global Myelodysplastic Syndrome Drug Revenue by Region in 2025 Figure 21. North America Myelodysplastic Syndrome Drug Market Size by Country in 2025 Figure 22. North America Myelodysplastic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 23. North America Myelodysplastic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Myelodysplastic Syndrome Drug Market Size by Country in 2025 Figure 27. Europe Myelodysplastic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 28. Europe Myelodysplastic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 29. Germany Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Asia Pacific Myelodysplastic Syndrome Drug Market Size by Country in 2025 Figure 35. Asia Pacific Myelodysplastic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 36. Asia Pacific Myelodysplastic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 37. China Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Japan Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. South Korea Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. India Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Australia Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. China Taiwan Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South America Myelodysplastic Syndrome Drug Market Size by Country in 2025 Figure 46. South America Myelodysplastic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 47. South America Myelodysplastic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 48. Mexico Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Brazil Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Argentina Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Middle East and Africa Myelodysplastic Syndrome Drug Market Size by Country in 2025 Figure 52. Middle East and Africa Myelodysplastic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 53. Middle East and Africa Myelodysplastic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 54. Turkey Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Saudi Arabia Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. UAE Myelodysplastic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Global Myelodysplastic Syndrome Drug Sales Market Share by Type (2021-2032) Figure 58. Global Myelodysplastic Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 59. Global Myelodysplastic Syndrome Drug Price (US$/Unit) by Type (2021-2032) Figure 60. Global Myelodysplastic Syndrome Drug Sales Market Share by Application (2021-2032) Figure 61. Global Myelodysplastic Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 62. Global Myelodysplastic Syndrome Drug Price (US$/Unit) by Application (2021-2032) Figure 63. Myelodysplastic Syndrome Drug Value Chain Figure 64. Myelodysplastic Syndrome Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Myelodysplastic Syndrome Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Immunomodulatory Drugs
  • Hypomethylating Drugs
Applications
  • Hospital
  • Ambulatory Nursing Center
  • Others
Companies covered
  • BluePoint Laboratories
  • Celgene Corporation
  • Lupin Ltd Corporation
  • Otsuka America Pharmaceutical
  • Reddy's Laboratories
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries
  • Amgen
  • Johnson & Johnson
  • Sandoz
  • Takeda

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Myelodysplastic Syndrome Drug Market Size (2021-2032)
  4. 2.2.2 Global Myelodysplastic Syndrome Drug Sales (2021-2032)
  5. 2.2.3 Global Myelodysplastic Syndrome Drug Market Average Price (2021-2032)
  6. 2.3 Myelodysplastic Syndrome Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Immunomodulatory Drugs
  9. 2.3.3 Hypomethylating Drugs
  10. 2.4 Myelodysplastic Syndrome Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Ambulatory Nursing Center
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Myelodysplastic Syndrome Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Myelodysplastic Syndrome Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Myelodysplastic Syndrome Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Myelodysplastic Syndrome Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Myelodysplastic Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Myelodysplastic Syndrome Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Myelodysplastic Syndrome Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Myelodysplastic Syndrome Drug, Established Date
  9. 3.9 Global Myelodysplastic Syndrome Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 BluePoint Laboratories
  2. 4.1.1 BluePoint Laboratories Company Information
  3. 4.1.2 BluePoint Laboratories Business Overview
  4. 4.1.3 BluePoint Laboratories Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 BluePoint Laboratories Myelodysplastic Syndrome Drug Product Portfolio
  6. 4.1.5 BluePoint Laboratories Recent Developments
  7. 4.2 Celgene Corporation
  8. 4.2.1 Celgene Corporation Company Information
  9. 4.2.2 Celgene Corporation Business Overview
  10. 4.2.3 Celgene Corporation Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Celgene Corporation Myelodysplastic Syndrome Drug Product Portfolio
  12. 4.2.5 Celgene Corporation Recent Developments
  13. 4.3 Lupin Ltd Corporation
  14. 4.3.1 Lupin Ltd Corporation Company Information
  15. 4.3.2 Lupin Ltd Corporation Business Overview
  16. 4.3.3 Lupin Ltd Corporation Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Lupin Ltd Corporation Myelodysplastic Syndrome Drug Product Portfolio
  18. 4.3.5 Lupin Ltd Corporation Recent Developments
  19. 4.4 Otsuka America Pharmaceutical
  20. 4.4.1 Otsuka America Pharmaceutical Company Information
  21. 4.4.2 Otsuka America Pharmaceutical Business Overview
  22. 4.4.3 Otsuka America Pharmaceutical Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Otsuka America Pharmaceutical Myelodysplastic Syndrome Drug Product Portfolio
  24. 4.4.5 Otsuka America Pharmaceutical Recent Developments
  25. 4.5 Reddy's Laboratories
  26. 4.5.1 Reddy's Laboratories Company Information
  27. 4.5.2 Reddy's Laboratories Business Overview
  28. 4.5.3 Reddy's Laboratories Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Reddy's Laboratories Myelodysplastic Syndrome Drug Product Portfolio
  30. 4.5.5 Reddy's Laboratories Recent Developments
  31. 4.6 Shilpa Medicare Limited
  32. 4.6.1 Shilpa Medicare Limited Company Information
  33. 4.6.2 Shilpa Medicare Limited Business Overview
  34. 4.6.3 Shilpa Medicare Limited Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shilpa Medicare Limited Myelodysplastic Syndrome Drug Product Portfolio
  36. 4.6.5 Shilpa Medicare Limited Recent Developments
  37. 4.7 Sun Pharmaceutical Industries
  38. 4.7.1 Sun Pharmaceutical Industries Company Information
  39. 4.7.2 Sun Pharmaceutical Industries Business Overview
  40. 4.7.3 Sun Pharmaceutical Industries Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sun Pharmaceutical Industries Myelodysplastic Syndrome Drug Product Portfolio
  42. 4.7.5 Sun Pharmaceutical Industries Recent Developments
  43. 4.8 Amgen
  44. 4.8.1 Amgen Company Information
  45. 4.8.2 Amgen Business Overview
  46. 4.8.3 Amgen Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Amgen Myelodysplastic Syndrome Drug Product Portfolio
  48. 4.8.5 Amgen Recent Developments
  49. 4.9 Johnson & Johnson
  50. 4.9.1 Johnson & Johnson Company Information
  51. 4.9.2 Johnson & Johnson Business Overview
  52. 4.9.3 Johnson & Johnson Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Johnson & Johnson Myelodysplastic Syndrome Drug Product Portfolio
  54. 4.9.5 Johnson & Johnson Recent Developments
  55. 4.10 Sandoz
  56. 4.10.1 Sandoz Company Information
  57. 4.10.2 Sandoz Business Overview
  58. 4.10.3 Sandoz Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sandoz Myelodysplastic Syndrome Drug Product Portfolio
  60. 4.10.5 Sandoz Recent Developments
  61. 4.11 Takeda
  62. 4.11.1 Takeda Company Information
  63. 4.11.2 Takeda Business Overview
  64. 4.11.3 Takeda Myelodysplastic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Takeda Myelodysplastic Syndrome Drug Product Portfolio
  66. 4.11.5 Takeda Recent Developments
5 Global Myelodysplastic Syndrome Drug Market Scenario by Region
  1. 5.1 Global Myelodysplastic Syndrome Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Myelodysplastic Syndrome Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Myelodysplastic Syndrome Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Myelodysplastic Syndrome Drug Sales by Region: 2027-2032
  5. 5.3 Global Myelodysplastic Syndrome Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Myelodysplastic Syndrome Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Myelodysplastic Syndrome Drug Revenue by Region: 2027-2032
  8. 5.4 North America Myelodysplastic Syndrome Drug Market Facts & Figures by Country
  9. 5.4.1 North America Myelodysplastic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Myelodysplastic Syndrome Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Myelodysplastic Syndrome Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Myelodysplastic Syndrome Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Myelodysplastic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Myelodysplastic Syndrome Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Myelodysplastic Syndrome Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Myelodysplastic Syndrome Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Myelodysplastic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Myelodysplastic Syndrome Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Myelodysplastic Syndrome Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Myelodysplastic Syndrome Drug Market Facts & Figures by Country
  35. 5.7.1 South America Myelodysplastic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Myelodysplastic Syndrome Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Myelodysplastic Syndrome Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Myelodysplastic Syndrome Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Myelodysplastic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Myelodysplastic Syndrome Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Myelodysplastic Syndrome Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Myelodysplastic Syndrome Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Myelodysplastic Syndrome Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Myelodysplastic Syndrome Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Myelodysplastic Syndrome Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Myelodysplastic Syndrome Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Myelodysplastic Syndrome Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Myelodysplastic Syndrome Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Myelodysplastic Syndrome Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Myelodysplastic Syndrome Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Myelodysplastic Syndrome Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Myelodysplastic Syndrome Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Myelodysplastic Syndrome Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Myelodysplastic Syndrome Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Myelodysplastic Syndrome Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Myelodysplastic Syndrome Drug Value Chain Analysis
  2. 8.1.1 Myelodysplastic Syndrome Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Myelodysplastic Syndrome Drug Production Mode & Process
  5. 8.2 Myelodysplastic Syndrome Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Myelodysplastic Syndrome Drug Distributors
  8. 8.2.3 Myelodysplastic Syndrome Drug Customers
9 Global Myelodysplastic Syndrome Drug Analyzing Market Dynamics
  1. 9.1 Myelodysplastic Syndrome Drug Industry Trends
  2. 9.2 Myelodysplastic Syndrome Drug Industry Drivers
  3. 9.3 Myelodysplastic Syndrome Drug Industry Opportunities and Challenges
  4. 9.4 Myelodysplastic Syndrome Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst